Once-daily grazoprevir/elbasvir is effective in patients infected with chronic hepatitis C

Results presented today at The International Liver Congress™ 2015 show that a 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir is effective and well-tolerated in treatment-naive (TN) patients infected with chronic hepatitis C virus genotypes -1, -4 or -6, including those with compensated cirrhosis. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail